GRAIL (GRAL) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Grail, Agility Robotics, and Sandisk could deliver multibagger gains in the future.…

GRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST Company Participants Aaron Freidin - CFO & Head of Corporate Development Conference Call Participants Douglas Schenkel - UBS Inves…

GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.…

GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript…

GRAIL NASDAQ: GRAL reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening te…

FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% t…

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.…

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the …

SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the…

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value o…

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands d…

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.…

Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.…

Gilead Sciences (NASDAQ: GILD - Get Free Report) and GRAIL (NASDAQ: GRAL - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their e…

Grail and Veeva Systems could be well insulated from near-term headwinds.…

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.…

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts…

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.…

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday. The stock traded as high as $141.97 and last traded at $144.0280. Approximately 113,792 shares were traded during trad…

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The company traded as high as $151.46 and last traded at $140.12, with a volume of 1920136 shares trading hands. The stock had pr…

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.…

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics …

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the for…

MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 19. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

